ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
ZyVersa Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 8.10M shares outstanding
USZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders.
The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions.
The company maintains its corporate headquarters in Weston, Florida.
Leadership
Gregory Freitag
Director
James Sapirstein
Director
Karen A. Cashmere
Chief Commercial Officer
Min Chul Park, Ph.D.
Director
Employees
7
Country
US
Sector
Healthcare
Website
zyversa.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Cashmere Karen A. | Chief Commercial Officer | Grant/Award | 48.1K | -- | Jul 11, 2025 |
 Guzman Pablo A. | Chief Medical Officer | Grant/Award | 48.9K | -- | Jul 11, 2025 |
 Freitag Gregory Gene | Director | Grant/Award | 11.1K | -- | Jul 11, 2025 |
 Glover Stephen C. | Chief Executive Officer | Grant/Award | 136.9K | -- | Jul 11, 2025 |
 Finizio Robert G | Director | Grant/Award | 11.1K | -- | Jul 11, 2025 |
 Wolfe Peter | Chief Financial Officer | Grant/Award | 60.1K | -- | Jul 11, 2025 |
| Name | Shares | % | Source |
|---|---|---|---|
Armistice Capital, LLC · may incl. warrants· filed Aug 2025 | 416.8K | 5.1% | 13G |
Anson Funds Management LP · may incl. warrants· filed Nov 2024 | 54.1K | 0.7% | 13G |
Ionic Ventures, LLC · may incl. warrants· stale · filed Feb 2024 | 5.2K | 0.1% | 13G |
INCON Co., Ltd. · may incl. warrants· stale · filed Jan 2024 | 4.3K | 0.1% | 13G |
Guerra Advisors Inc | 7 | 0.0% | 13F |
Insiders
- Cashmere Karen A.Chief Commercial Officer
- Guzman Pablo A.Chief Medical Officer
- Freitag Gregory GeneDirector
- Glover Stephen C.Chief Executive Officer
- Finizio Robert GDirector
- Wolfe PeterChief Financial Officer
- Park Min-ChulDirector
- SAPIRSTEIN JAMESDirector
Top institutional holders
based on 8.10M shares outstanding
US30d Avg
26.99K
60d Avg
14.66K
90d Avg
11.94K